Purple biotech reports preclinical proof of concept for its tribody platform technology

Contribution of nk cells engager arm and conditionally activated t cell engager demonstrated cleavable capping technology confines therapeutic activity to the local tumor micro environment which increases the anticipated therapeutic window in patients rehovot, israel, march 14, 2024 (globe newswire) -- purple biotech ltd. ("purple biotech" or "the company") (nasdaq/tase: ppbt), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today reported preclinical proof of concept data for its conditionally-activated tri-specific antibody platform.
PPBT Ratings Summary
PPBT Quant Ranking